Short sellers are on the move. Data as of September 24 shows some sharp shifts in the past seven days — and a few names are flashing real squeeze risk.
MRNA is the standout cover story. Short interest dropped nearly 2 percentage points to 8.1% of free float. Positive ESMO cancer vaccine data sent the stock racing past $200. Bears who stayed short are nursing heavy losses.
SPCX, the newly listed SpaceX entity, tells the opposite story. SI jumped almost 10 points in a week to 30.6% of free float. That is a major bearish build for a stock with a $1.2 trillion market cap. Cost to borrow is still low at 0.56%, so shorts are not yet squeezed for cash.
GME jumped from 0.9% to 7.5% SI in just seven days. Bears are piling back in despite the meme stock's history of punishing short sellers. With availability still at 233% of SI, shares to borrow remain plentiful — for now.
MMED caught the eye of high-score screeners. SI sits at 68.3% of free float after rising nearly 30 points this week. MiniMed's short score of 90 signals bears are deeply committed.
also saw a modest SI build to 8.1%, up from 6.2%, as earnings pressure mounts ahead of results.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
